Monosodium Glutamate (MSG) induced Obesity Modeling & Pharmacodynamics Service
Creative Biolabs offers a variety of well-established models for evaluating obesity therapies, including the monosodium glutamate (MSG)-induced obesity model, which provides an ideal platform for investigating the underlying mechanisms of obesity and testing potential therapeutic agents.
Introduction
Obesity is a complex, multifactorial disease characterized by an excessive accumulation of body fat. It is associated with various comorbidities, including cardiovascular diseases, diabetes, hypertension, and metabolic syndrome. The global prevalence of obesity has been rising at an alarming rate, making it one of the leading public health concerns. Obesity can be caused by a combination of genetic, environmental, and lifestyle factors, and its management often involves weight reduction strategies such as diet, exercise, and pharmacotherapy. Obesity models are essential tools in preclinical research to evaluate the efficacy of anti-obesity drugs and treatments.
Disease Models and Applications
The Monosodium Glutamate (MSG)-Induced Obesity Model is widely used in obesity research to simulate diet-induced obesity in rodents. MSG, a flavor enhancer, is administered to neonate rats or mice, causing damage to hypothalamic neurons, which in turn disrupts the regulation of appetite and energy balance. This results in increased food intake, impaired satiety, and a tendency to develop obesity. This model is especially useful for studying neuroendocrine dysfunction and the role of the hypothalamus in obesity. It is characterized by rapid weight gain, elevated adiposity, and insulin resistance, making it an excellent tool for investigating metabolic disorders related to obesity. While this model offers valuable insights into the neural mechanisms of obesity, its main limitation is that it does not fully replicate the human condition of obesity, which often involves complex interactions between environmental and genetic factors.
- Simulates: The MSG-Induced Obesity Model simulates obesity, particularly through mechanisms related to neuroendocrine dysfunction. It is particularly useful for studying the role of the hypothalamus in regulating food intake and energy expenditure.
- Evaluates Drugs: This model is ideal for evaluating anti-obesity drugs, such as appetite suppressants, insulin sensitizers, and compounds that regulate adipogenesis or thermogenesis. It can also be used to assess the efficacy of drugs targeting metabolic disorders like insulin resistance and hyperglycemia.
Measurements
We offer a comprehensive set of measurements for evaluating drug efficacy in the MSG-induced obesity model, utilizing a range of cutting-edge techniques, including but not limited to:
- General observations: body weight, food intake, metabolic rate, and changes in behavior or activity levels.
- Immunohistochemistry: staining for hypothalamic changes, adipose tissue inflammation, and neural damage.
- Cytokine profiling (e.g., ELISA): measurement of inflammatory markers such as TNF-α, IL-6, and IL-1β in plasma and tissues.
- Metabolic parameters: blood glucose levels, insulin sensitivity, and lipid profiles.
- Gene/protein expression: RT-PCR and Western blotting to assess the expression of genes involved in metabolic pathways, adipogenesis, and inflammation.
In addition to these established metrics, our scientific team offers guidance in model selection, experimental design, and data analysis, ensuring that your project is carried out with precision and relevance to your research goals.
Related Services
In addition to the monosodium glutamate (MSG)-Induced obesity model, we also offer a wide range of models for other diseases. These models enable comprehensive evaluation across diverse therapeutic areas.
- High-Fat Diet induced Obesity Model
- High-Fat & High-Carbohydrate Diet induced Obesity Model
- Cafeteria Diet induced Obesity Model
- ob/ob Obesity Mouse Model
Advantages
- Expertise and Experience: Decades of experience in providing specialized obesity models and preclinical research support.
- Customizable Models: Tailored obesity models, including the MSG-Induced Obesity Model, to suit your specific research needs.
- Advanced Technologies: Use of cutting-edge technologies for accurate and reliable results.
- Comprehensive Support: Expert assistance in experimental design, model selection, and data analysis.
- High-Quality Standards: Strict quality control processes to ensure reproducibility and reliability of results.
Work with Us
- Summarize the project requirements and fill in the information collection form.
- Sign a CDA from both parties to further communicate information, such as targets.
- Select an animal model, discuss experimental design, and determine assay parameters.
- Project costing and project schedule forecasting.
- We provide a detailed project plan, including the required sample quantities, methods, and protocols.
- Both parties confirm the project details and start the project.
- Confirm the timeline of the project.
- We provide periodic results and information on the animal's condition.
- We will work together to make project adjustments as necessary.
- We provide a comprehensive project report promptly.
- We arrange transportation for the produced samples.
- We provide a discussion of the project results and help to arrange the next steps.
- Data storage and archiving.
FAQs
-
Q: What is the MSG-Induced Obesity Model used for?
A: The MSG-Induced Obesity Model is primarily used to study neuroendocrine dysfunctions in obesity and to evaluate the efficacy of anti-obesity drugs.
-
Q: How does the MSG-Induced Obesity Model work?
A: MSG is administered to neonatal rodents to induce hypothalamic damage, leading to increased food intake and the development of obesity. This model is particularly useful for studying the neuroendocrine aspects of obesity.
-
Q: How long does it take for obesity to develop in the MSG model?
A: Significant obesity typically develops in mice within 3-4 weeks following MSG treatment.
-
Q: What are the advantages of using this model?
A: The MSG model offers insights into the neuroendocrine mechanisms of obesity, particularly the role of the hypothalamus in regulating appetite and energy balance.
-
Q: What measurements are taken in the MSG-Induced Obesity Model?
A: Key measurements include body weight, food intake, metabolic rate, blood glucose, insulin sensitivity, lipid profiles, cytokine levels, and gene/protein expression related to metabolic pathways.
Published Data
Fig. 1 Piperine reduced mesenteric fat accumulation and body weight but not food intake and Lee's index.1
This study investigates the effects of piperine on obesity-induced insulin resistance in a monosodium glutamate (MSG)-induced obesity model. The impact of piperine on body weight, mesenteric fat accumulation, Lee's index, glycolipid metabolism, and insulin sensitivity was assessed in MSG-obese insulin-resistant mice. The results demonstrated that MSG administration led to a significant increase in body weight and mesenteric fat accumulation in the obese insulin-resistant mice (Model: 70.20 ± 2.54 g, p < 0.0001) compared to normal mice (Normal: 48.09 ± 1.43 g). However, piperine treatment resulted in a noticeable reduction in both body weight and mesenteric fat (Fig. 1a-b). From the 4th week of treatment, the body weight of piperine-treated mice began to decline, eventually reaching 53.0 ± 2.88 g, which was significantly lower (p < 0.001) than that of the MSG-obese mice (70.20 ± 2.54 g). No significant differences were observed between the model and piperine-treated groups in terms of daily food intake or Lee's index (p > 0.05, Fig. 1c-d).
Reference
- Liu, Chaolong et al. "Piperine ameliorates insulin resistance via inhibiting metabolic inflammation in monosodium glutamate-treated obese mice." BMC Endocrine Disorders vol. 20,1 152. 7 Oct. 2020, DOI:10.1186/s12902-020-00617-1. Distributed under an Open Access license CC BY 4.0, without modification.
For Research Use Only.